John Ning, MD, PhD

Senior Vice President, Oncology

Dr. Ning is the clinical and program lead for HUYABIO’s Oncology program. With over 25 years experience in clinical development, operations, translational research, medical affairs, pharmacovigilance and drug safety in both pharmaceutical and biotech, he served as SillaJen’s Biotherapeutics Chief Medical Officer, focusing on immuno-oncology therapeutic development. At Genentech’s Oncology Product Development Clinical and Safety Sciences, John was involved with the development of many successful drugs on the market today. Prior companies include Bristol-Myers Squibb and Roche Laboratory. Dr. Ning received his PhD in Biochemistry and Molecular Biology and MD from Virginia Commonwealth University School of Medicine, an MS in Pharmacology and an MS in Medical Laboratory Sciences from Northeastern University, and a BS in Chemistry from Massachusetts Institute of Technology.